Immunic, Inc. announced the resignation of Dr. Duane Nash from its board of directors, effective September 10, 2026. The company stated that the resignation was not due to any disagreements and subsequently reduced its board size from ten to nine members. This news follows recent positive analyst coverage for Immunic's multiple sclerosis drug, vidofludimus calcium, which is nearing Phase 3 trial results.

Erlich Law Firm secured a significant procedural victory against Southwest Airlines, as Judge Jacqueline Scott Corley denied Southwest's motion for summary judgment. This ruling allows a class action lawsuit, brought by flight attendants challenging Southwest's attendance policy regarding FMLA leave, to proceed to a jury trial on October 13, 2026. The case questions whether taking protected leave put employees closer to job loss and seeks accountability for alleged resulting job losses and income impact.

Smith Chas P & Associates PA Cpas reduced its stake in Walmart Inc. (WMT) by 3.7% in Q2 2026, selling 26,996 shares but still holding 694,499 shares valued at $78.66 million. Walmart represents 3.8% of the firm's portfolio. Despite a recent decline in stock price and some analysts lowering price targets, the company maintains a "Moderate Buy" consensus rating, with its latest quarterly earnings exceeding expectations.

Bullseye Investment Management LLC has made a new investment of $1.14 million in American Express Company (NYSE:AXP), acquiring 3,373 shares during the second quarter. This move makes AXP the firm's 27th largest holding, representing 0.6% of its portfolio, while institutional investors collectively own 84.33% of the stock. American Express reported strong quarterly results with EPS of $4.53 and revenue up 10% year-over-year, exceeding analyst expectations, and has issued positive fiscal 2026 EPS guidance.

Apollo Global Management is reportedly in discussions to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, in a deal potentially worth around $20 billion. J&J is considering either a sale or spinning off the unit as a publicly traded company. This move aligns with J&J's strategy to focus on higher-growth healthcare segments and follows previous reports of their intent to separate the orthopedics unit.

Smith Chas P & Associates PA Cpas reduced its stake in Lockheed Martin Corporation by 3.2% in the second quarter, selling 2,881 shares and retaining 88,040 shares valued at approximately $44.9 million. Analyst sentiment for LMT is mixed but has recently improved, with UBS upgrading the stock to "buy" and a consensus "hold" rating with an average price target of $637.56. Lockheed Martin also reported strong quarterly results, exceeding EPS and revenue expectations, and declared a $3.45 quarterly dividend.

Smith Chas P & Associates PA Cpas has a $46.21 million stake in Merck & Co., Inc. (MRK), despite reducing its holdings by 2.2% in the second quarter. Institutional investors hold a significant 76.07% of Merck's stock, while company insiders have sold nearly $30 million worth of shares in the last 90 days. Analysts maintain a "Moderate Buy" rating for Merck, with an average price target of $151.32, as the company reported strong quarterly revenue and declared a dividend.

InterDigital is demanding 101.7 million euros in damages from Disney in Germany for patent infringement related to HDR streaming on Disney+. The claim covers the period from March 2020 to the end of 2025, and follows a preliminary injunction issued by the Munich I Regional Court in November 2025. Disney has removed Dolby Vision and temporarily 4K resolution from its German offering, leading to special termination rights for premium customers.

Talon Private Wealth LLC has acquired a new stake in Advanced Micro Devices (NASDAQ:AMD), purchasing 2,328 shares valued at approximately $1.35 million in the second quarter. This move comes as institutional investors collectively own 71.34% of AMD, and the semiconductor manufacturer recently reported strong quarterly earnings with 50.1% year-over-year revenue growth. Despite a broadly bullish outlook from Wall Street with a "Moderate Buy" rating and a $565.12 price target, analysts note risks related to AMD's valuation and intense competition in the AI chip market.

This article announces that Immunic Inc. filed a Form 8K on September 11. It provides a brief mention of the filing, along with the company's stock symbol IMUX and its recent price performance. The main body of the article appears to be a standard template from Investing.com with market data and news unrelated to the specific Form 8K filing.